

The Medical Letter[®]

on Drugs and Therapeutics

COMPARISON CHART: Interleukin (IL) Antagonists for Moderate To Severe Atopic Dermatitis

Updated January 30, 2025

The Medical Letter[®]

Because the source matters.

To support more content like this, please consider making a [donation](#) or becoming a [subscriber](#).

The Medical Letter is a nonprofit organization* that relies solely on subscription fees and donations to support our mission of providing objective, practical, and timely information on drugs and therapeutics.

Our work relies on support from people like you who value credible, unbiased drug information that is free of any commercial interest.

For more information visit our [website](#) or call Customer Service at: 800-211-2769

*The Medical Letter is a nonprofit, tax-exempt organization under Section 501(C)(3) of the Internal Revenue Code. Donations are tax-deductible as allowed by law.

INTERLEUKIN (IL) ANTAGONISTS FOR MODERATE TO SEVERE ATOPIC DERMATITIS

Drug/Formulations	Class	Approved Age	Efficacy at 16 Weeks ¹	Usual Adult Dosage	Cost ²
Dupilumab – Dupixent (Sanofi/Regeneron) 200 mg/1.14 mL, 300 mg/2 mL prefilled pens, syringes	IL-4 and IL-13 inhibitor	≥6 months old	With topical steroid (adults): IGA response rate: 39% EASI-75: 69% (package insert)	600 mg SC at wk 0, then 300 mg SC q2 wks	\$3993.00
Lebrikizumab – Ebglyss (Lilly) 250 mg/2 mL prefilled pens, syringes	IL-13 antagonist	≥12 years old (weight ≥40 kg)	With topical steroid: IGA response rate: 41% EASI-75: 70% (JAMA Dermatol 2023;159:182)	Initial: 500 mg SC at wks 0 and 2, then 250 mg SC q2 wks Maintenance: 250 mg SC q4 wks if adequate response at wk 16	7000.00
Tralokinumab – Adbry (Leo) 150 mg/1 mL prefilled syringes; 300 mg/2 mL auto-injectors	IL-13 antagonist	≥12 years old	With topical steroid: IGA response rate: 39% EASI-75: 56% (Br J Dermatol 2021; 184:450)	Initial: 600 mg SC at wk 0, then 300 mg SC q2 wks Maintenance: 300 mg SC q4 wks if >100 kg and clear/almost clear skin at wk 16	4070.00
Nemolizumab – Nemluvio (Galderma) 30 mg/mL prefilled pens	IL-31 antagonist	≥12 years old	With topical steroid +/- calcineurin inhibitor: IGA response rate: 36-38% EASI-75: 42-44% (Lancet 2024; 404:445)	Initial: 60 mg SC at wk 0, then 30 mg SC q4 wks Maintenance: 30 mg SC q8 wks if clear/almost clear skin at wk 16	4240.00

1. IGA response rate is defined as an improvement in the score on the clinician-rated Investigator's Global Assessment (IGA) scale from 3 to 4 (signifying moderate or severe disease) at baseline to 0 or 1 (signifying clear or almost clear skin). EASI-75 is defined as a ≥75% improvement in the Eczema Area and Severity Index (EASI) score.

2. Approximate WAC for 4 weeks' treatment at the usual adult maintenance dosage. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. January 5, 2025. Reprinted with permission by First Databank, Inc. All rights reserved. ©2025. www.fdbhealth.com/policies/drug-pricing-policy.